Literature DB >> 8514066

The non-bleeding visible vessel versus the sentinel clot: natural history and risk of rebleeding.

M L Freeman1, O W Cass, C J Peine, G R Onstad.   

Abstract

Non-bleeding visible vessel and sentinel clot are terms used interchangeably to describe protuberances in the base of ulcers that have recently bled, but a consensus as to their definition or natural history does not exist. In patients with severe ulcer hemorrhage, non-bleeding protuberances were classified as vessels, with or without a small attached clot, or as sentinel clots, according to a schema based on the appearance of the protuberance at endoscopy but not subjected to pathologic correlation. Endoscopic therapy was not performed at the index endoscopic evaluation, and natural evolution was prospectively documented with daily videoendoscopy. Eleven (46%) of 24 patients with non-bleeding protuberances had rebleeding. Independent classification by three authors concurred in 18 (75%) of 24 lesions. Ten (91%) of 11 vessels with or without attached clot rebled versus 0 (0%) of 7 sentinel clots and 1 (17%) of 6 lesions without unanimous classification (p < 0.01, vessels versus other groups). Rebleeding occurred in 5 (71%) of 7 nonpigmented (pale or white), 6 (38%) of 16 red or purple, and 0 (0%) of 1 black protuberances. In general, vessels persisted until rebleeding, whereas sentinel clots disappeared within 1 to 3 days. We conclude that nonbleeding protuberances in ulcer bases can be separated into vessels, which have a high risk of rebleeding, and sentinel clots, which have a low risk of rebleeding.

Entities:  

Mesh:

Year:  1993        PMID: 8514066     DOI: 10.1016/s0016-5107(93)70106-6

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  9 in total

1.  Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding.

Authors:  Dennis M Jensen; Gordon V Ohning; Thomas O G Kovacs; Kevin A Ghassemi; Rome Jutabha; Gareth S Dulai; Gustavo A Machicado
Journal:  Gastrointest Endosc       Date:  2015-08-28       Impact factor: 9.427

2.  Endoscopic intervention in bleeding peptic ulcer.

Authors:  K R Palmer; C P Choudari
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

Review 3.  Management of gastrointestinal hemorrhage.

Authors:  R J Hilsden; E A Shaffer
Journal:  Can Fam Physician       Date:  1995-11       Impact factor: 3.275

4.  Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study.

Authors:  H J Lin; C L Perng; F Y Lee; C H Lee; S D Lee
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

5.  Endoscopic therapy for peptic ulcer hemorrhage: practice variations in a multi-center U.S. consortium.

Authors:  Brintha K Enestvedt; Ian M Gralnek; Nora Mattek; David A Lieberman; Glenn M Eisen
Journal:  Dig Dis Sci       Date:  2010-06-29       Impact factor: 3.199

6.  Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer.

Authors:  E Brullet; R Campo; X Calvet; D Coroleu; E Rivero; J Simó Deu
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

Review 7.  A practical guide to the management of bleeding ulcers.

Authors:  C Villanueva; J Balanzó
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

8.  Endoscopic Doppler ultrasound versus endoscopic stigmata-directed management of acute peptic ulcer hemorrhage: a multimodel cost analysis.

Authors:  Victor K Chen; Richard C K Wong
Journal:  Dig Dis Sci       Date:  2006-11-16       Impact factor: 3.487

9.  A real world report on intravenous high-dose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding.

Authors:  Lung-Sheng Lu; Sheng-Chieh Lin; Chung-Mou Kuo; Wei-Chen Tai; Po-Lin Tseng; Kuo-Chin Chang; Chung-Huang Kuo; Seng-Kee Chuah
Journal:  Gastroenterol Res Pract       Date:  2012-07-11       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.